Table 3 Incremental (Δ) number of working days saved (WDS) thanks to the different recovery assessment strategies (effectiveness), incremental (Δ) cost, incremental cost-effectiveness ratio (ICER) and incremental net monetary benefit (INMB) between swab-based strategy (SW) and the three different symptoms-based and comparing the competing symptoms-based strategies with swabs scheduled at 10 and 17 days (SY10-17), 14 and 17 days (SY14-17) or only 17 days (SY17)
Δ effectiveness (WDS) | Δ cost (€) | ICER (€/WDS) | INMB (€) | |
|---|---|---|---|---|
Strategies | ||||
SW | Reference | Reference | Reference | Reference |
SY10-17 | 43.6 (39.7; 47.5) | − 2508 (− 8100; − 666) | Dominates | 9480 (7231; 15,349) |
SY14-17 | 51.1 (47.1; 55.2) | − 2490 (− 8043; − 662 | Dominates | 10,662 (8408; 16,314) |
SY17 | 31.0 (27.6; 34.6) | − 2966 (− 9589; − 789) | Dominates | 7933 (5420; 14,647) |
Strategies | ||||
SY10-17 | Reference | Reference | Reference | Reference |
SY14-17 | 7.5 (3.8; 11.2) | 18 (4; 55) | 2 | 1182 (590; 1779) |
SY17 | − 12.5 (− 15.6; − 9.5) | − 458 (− 1484; − 122) | 37 | − 1547 (− 2306; − 473) |
Strategies | ||||
SY14-17 | Reference | Reference | Reference | Reference |
SY17 | − 20.0 (− 23.3; − 16.8) | − 476 (− 1551; − 126) | 24 | − 2730 (− 3529; − 1612) |